Huons introduce asthma treatment with new combination for first time in Korea

Published: 2017-12-26 16:23:26

Updated: 2017-12-28 16:05:35

Huons(CEO Gi-Ahn Eum), a subsidiary of Huons Global, signed an exclusive distribution license agreement of ‘Zephirus,’ a inhaled capsule for the treatment of asthma, in Korea with Belgian Laboratoires SMB S.A.(SMB) at its headquarters on the 19th.

‘Zephirus,’ a fixed-capacity drug in combination of ‘budesonide,’ a first inhaled corticosteroid(ICS) which relieves pulmonary infections, and ‘sa...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.